

COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

RESEARCH REPORT



COMPANION DIAGNOSTIC MARKETS

THE FUTURE OF DIAGNOSTICS

BY FUNDING SOURCE AND APPLICATION WITH CUSTOMIZED
FORECASTING/ANALYSIS, COVID UPDATES,
AND EXECUTIVE AND CONSULTANT GUIDES
2021-2025



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Market Guides	20
1.1	Companion Diagnostic Market - Strategic Situation Analysis	21
1.2	Guide for Executives, Marketing, Sales and Business Development Staff	24
1.3	Guide for Management Consultants and Investment Advisors	26
2	Introduction and Market Definition	27
2.1	What are Companion Diagnostics?	28
2.2	The Personalized Medicine Revolution	31
2.3	Market Definition	33
2.3.1	Revenue Market Size	33
2.4	Methodology	34
2.4.1	Authors	34
2.4.2	Sources	35
2.5	A Spending Perspective on Clinical Laboratory Testing	36
2.5.1	U.S. Medicare Expenditures for Laboratory Testing	36
3	Market Overview	38
3.1	Players in a Dynamic Market	39
3.1.1	Academic Research Lab	40
3.1.2	Diagnostic Test Developer	40
3.1.3	Instrumentation Supplier	40
3.1.4	Distributor and Reagent Supplier	41

3.1.5	Independent Testing Lab.....	41
3.1.6	Public National/regional lab	42
3.1.7	Hospital lab	42
3.1.8	Physician Office Labs	43
3.1.9	Audit Body	43
3.1.10	Certification Body.....	43
3.2	Personalized Medicine and Companion Diagnostics	45
3.2.1	Basics	45
3.2.2	Method.....	46
3.2.3	Disease risk assessment	46
3.2.4	Applications.....	46
3.2.5	Diagnosis and intervention	47
3.2.5.1	Companion Diagnostics	48
3.2.6	Drug development and usage	48
3.2.7	Respiratory proteomics	49
3.2.8	Cancer genomics	50
3.2.9	Population screening	51
3.2.10	Challenges.....	51
3.2.11	Regulatory oversight	51
3.2.12	Intellectual property rights.....	52
3.2.13	Reimbursement policies.....	52
3.2.14	Patient privacy and confidentiality	52
3.3	Chromosomes, Genes and Epigenetics	54
3.3.1	Chromosomes	54

3.3.2	Genes	56
3.3.3	Epigenetics	59
3.4	Cancer Genes.....	60
3.4.1	Germline vs Somatic	62
3.4.2	Changing Clinical Role	64
3.5	Structure of Industry Plays a Part.....	65
3.5.1	New Pharmaceutical Funding Market	65
3.5.2	Economies of Scale.....	65
3.5.2.1	Hospital vs. Central Lab.....	66
3.5.3	Physician Office Labs	67
3.5.4	Physicians and POCT.....	67
4	Market Trends	69
4.1	Factors Driving Growth	70
4.1.1	Level of Care.	70
4.1.2	Immuno-oncology.....	71
4.1.3	Liability.....	71
4.1.4	Aging Population.....	71
4.2	Factors Limiting Growth	73
4.2.1	State of knowledge.....	73
4.2.2	Genetic Blizzard.....	74
4.2.3	Protocol Resistance.....	74
4.2.4	Regulation and coverage.....	74
4.3	Instrumentation and Automation	75
4.3.1	Instruments Key to Market Share.....	75

4.3.2	Bioinformatics Plays a Role	75
4.4	Diagnostic Technology Development	76
4.4.1	Next Generation Sequencing Fuels a Revolution.....	77
4.4.2	Single Cell Genomics Changes the Picture.	78
4.4.3	Pharmacogenomics Blurs Diagnosis and Treatment.....	79
4.4.4	CGES Testing, A Brave New World.	79
4.4.5	Biochips/Giant magneto resistance based assay.....	80
5	Companion Diagnostics Recent Developments.....	81
5.1	Recent Developments – Importance and How to Use This Section	82
5.1.1	Importance of These Developments	82
5.1.2	How to Use This Section.....	82
5.2	HTG Molecular Diagnostics 2020 Revenues Fall 56 Percent	82
5.3	Oncocyte Details Expansions Plans	83
5.4	Agilent Acquires Resolution Biosciences	87
5.5	Qiagen, Inovio Expand CDx Partnership.....	89
5.6	AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance	90
5.7	NeoGenomics to Grow Through CDx Agreements, Acquisitions.....	91
5.8	Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction	96
5.9	Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform	100
5.10	FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies	101
5.11	Promega to Develop MSI Assay as CDx.....	107
5.12	HTG Molecular Q2 Revenues Drop 66 Percent.....	107
5.13	Guardant Health to Develop CDx for Janssen	109
5.14	Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx	110

5.15	FDA Approval for FoundationOne®CDx.....	110
5.16	FDA finalizes CDx Guidance.....	111
5.17	QIAGEN Launches CDx Therascreen BRAF Test.....	113
5.18	Myriad Genetics Seeks Approval for Companion Diagnostic.....	114
5.19	ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx.....	115
5.20	QIAGEN Builds on Global Collaboration with Amgen	115
5.21	Foundation Medicine nabs 19th companion Dx.....	116
5.22	Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostics ...	117
5.23	Myriad Wins Japanese Approval for BRACAnalysis.....	119
5.24	Fujitsu Improves Efficiency in Cancer Genomic Medicine	121
5.25	Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results	123
5.26	Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership	124
5.27	Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer	125
5.28	Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic	127
5.29	Universal Genetic Testing for All Breast Cancer Patients	128
5.30	Exact Sciences buys Genomic Health	128
5.31	Biodesix Highlights Pipeline and Companion Diagnostic Development	131
6	Profiles of Key Players	133
6.1	10x Genomics, Inc.....	134
6.2	Abbott Diagnostics	135
6.3	AccuraGen Inc.	137
6.4	Adaptive Biotechnologies.....	138
6.5	Aethlon Medical	139
6.6	Agena Bioscience, Inc.	140

6.7	Agilent.....	142
6.8	Anchor Dx.....	144
6.9	ANGLE plc.....	145
6.10	ApoCell, Inc.....	146
6.11	ArcherDx, Inc.....	147
6.12	ARUP Laboratories.....	148
6.13	Asuragen.....	150
6.14	AVIVA Biosciences	152
6.15	Baylor Miraca Genetics Laboratories	153
6.16	Beckman Coulter Diagnostics.....	154
6.17	Becton, Dickinson and Company	155
6.18	BGI Genomics Co. Ltd	157
6.19	Bioarray Genetics.....	158
6.20	Biocartis.....	159
6.21	Biocept, Inc.....	160
6.22	Biodesix Inc.	161
6.23	BioFluidica.....	162
6.24	BioGenex	163
6.25	BioIVT	165
6.26	Biolidics Ltd.....	166
6.27	bioMérieux Diagnostics.....	167
6.28	Bioneer Corporation	170
6.29	Bio-Rad Laboratories, Inc.....	172
6.30	Bio-Reference Laboratories.....	174

6.31	Bio-Techne	175
6.32	Bioview	177
6.33	Bolidics	178
6.34	Boreal Genomics.....	179
6.35	Bristol-Myers Squibb.....	180
6.36	Cancer Genetics.....	182
6.37	Caris Molecular Diagnostics	184
6.38	Castle Biosciences, Inc.	185
6.39	CellMax Life	186
6.40	Cepheid (now Danaher).....	187
6.41	Charles River Laboratories.....	188
6.42	Chronix Biomedical.....	189
6.43	Circulogene.....	190
6.44	Clinical Genomics	191
6.45	Cynvenio.....	192
6.46	Cytolumina Technologies Corp.	193
6.47	CytoTrack.....	194
6.48	Datar Cancer Genetics Limited.....	195
6.49	Diagnologix LLC.....	196
6.50	Diasorin S.p.A.	197
6.51	Enzo Life Sciences, Inc.	198
6.52	Epic Sciences.....	200
6.53	Epigenomics AG.....	201
6.54	Eurofins Scientific	202

6.55	Exosome Diagnostics	204
6.56	Exosome Sciences.....	205
6.57	Fabric Genomics	206
6.58	Fluidigm Corp	207
6.59	Fluxion Biosciences.....	208
6.60	Foundation Medicine	209
6.61	Freenome.....	210
6.62	GeneFirst Ltd.....	212
6.63	Genetron Health (Beijing) Co., Ltd.	213
6.64	Genomic Health.....	214
6.65	GenomOncology.....	215
6.66	GILUPI Nanomedizin.....	216
6.67	Grail, Inc.....	217
6.68	Guardant Health	218
6.69	HaliuDx	219
6.70	HansaBiomed	220
6.71	HeiScreen.....	221
6.72	Helomics.....	222
6.73	Horizon Discovery	223
6.74	HTG Molecular Diagnostics	225
6.75	iCellate	226
6.76	Illumina	227
6.77	IncCell Dx.....	228
6.78	Inivata	229

6.79	Integrated Diagnostics	230
6.80	Invivogen	233
6.81	Invivoscribe	234
6.82	Janssen Diagnostics	235
6.83	MDNA Life SCIENCES, Inc.....	236
6.84	MDx Health	237
6.85	Menarini Silicon Biosystems	238
6.86	Millipore Sigma	239
6.87	Miltenyi Biotec	240
6.88	MIODx.....	241
6.89	miR Scientific.....	242
6.90	Molecular MD	243
6.91	MyCartis	244
6.92	Myriad Genetics/Myriad RBM	245
6.93	NantHealth, Inc.	246
6.94	Natera	247
6.95	NeoGenomics	248
6.96	New Oncology	249
6.97	Novogene Bioinformatics Technology Co., Ltd.....	250
6.98	Oncocyte.....	252
6.99	OncoDNA	253
6.100	Ortho Clinical Diagnostics	254
6.101	Oxford Nanopore Technologies	255
6.102	Panagene.....	256

6.103	Perkin Elmer.....	257
6.104	Personal Genome Diagnostics.....	259
6.105	Personalis.....	260
6.106	Precipio	261
6.107	PrecisionMed	262
6.108	Promega	263
6.109	Qiagen Gmbh	265
6.110	Rarecells SAS.....	267
6.111	RareCyte.....	268
6.112	Roche Molecular Diagnostics	269
6.113	ScreenCell	271
6.114	Sense Biodetection.	272
6.115	Serametrix	273
6.116	Siemens Healthineers	274
6.117	Silicon Biosystems.....	277
6.118	simfo GmbH	278
6.119	Singlera Genomics Inc.....	279
6.120	Singulomics	280
6.121	SkylineDx	282
6.122	Stratos Genomics	283
6.123	Sysmex Inostics.....	284
6.124	Tempus Labs, Inc.	285
6.125	Thermo Fisher Scientific Inc.....	286
6.126	Thrive Earlier Detection	288

6.127	Todos Medical	289
6.128	Trovagene.....	290
6.129	Volition	291
6.130	Vortex Biosciences	292
7	The Global Market for Companion Diagnostics	293
7.1	Global Market Overview by Country	294
7.1.1	Table – Global Market by Country.....	294
7.1.2	Chart - Global Market by Country	295
7.2	Global Market by Application - Overview.....	296
7.2.1	Table – Global Market by Application	296
7.2.2	Chart – Global Market by Application – Base/Final Year Comparison	297
7.2.3	Chart – Global Market by Application – Base Year	298
7.2.4	Chart – Global Market by Application – Final Year.....	299
7.2.5	Chart – Global Market by Application – Share by Year.....	300
7.3	Global Market Funding Source - Overview	301
7.3.1	Table – Global Market by Funding Source	301
7.3.2	Chart – Global Market Funding Source – Base/Final Year Comparison	302
7.3.3	Chart – Global Market Funding Source – Base Year	303
7.3.4	Chart – Global Market Funding Source – Final Year.....	304
7.3.5	Chart – Global Market Funding Source – Share by Year	305
8	Global Companion Diagnostic Markets – By Application.....	306
8.1	Oncology.....	307
8.1.1	Table Oncology – by Country	307
8.1.2	Chart - Oncology Growth.....	308

8.2	Neurology	309
8.2.1	Table Neurology – by Country.....	309
8.2.2	Chart - Neurology Growth.....	310
8.3	Cardiology	311
8.3.1	Table Cardiology – by Country	311
8.3.2	Chart - Cardiology Growth.....	312
8.4	Other Application	313
8.4.1	Table Other Application – by Country.....	313
8.4.2	Chart - Other Application Growth	314
9	Global Companion Diagnostic Markets – Funding Source	315
9.1	Global Market Pharmaceutical.....	316
9.1.1	Table Pharmaceutical – by Country.....	316
9.1.2	Chart - Pharmaceutical Growth	317
9.2	Global Market Venture.....	318
9.2.1	Table Venture – by Country.....	318
9.2.2	Chart - Venture Growth	319
9.3	Global Market Clinical.....	320
9.3.1	Table Clinical – by Country.....	320
9.3.2	Chart - Clinical Growth	321
9.4	Global Market Other Funding.....	322
9.4.1	Table Other Funding – by Country	322
9.4.2	Chart - Other Funding Growth	323
10	Appendices.....	324
10.1	United States Medicare System: January 2021 Clinical Laboratory Fees Schedule .	325

10.2 Pharmacogenomic Biomarkers in Drug Labeling..... 428

Table of Tables

Table 1 Lab Spending 2014 to 2024	37
Table 2 Market Players by Type	39
Table 3 The Base Pairs.....	57
Table 4 Five Factors Driving Growth	70
Table 5 Four Factors Limiting Growth	73
Table 6 Key Diagnostic Laboratory Technology Trends	76
Table 7 Next Generation Sequencing Technologies – Speed and Cost	77
Table 8 Global Companion Diagnostic Market by Region.....	294
Table 9 Global Market by Application	296
Table 10 Global Market by Funding Source	301
Table 11 Oncology by Country	307
Table 12 Neurology by Country.....	309
Table 13 Cardiology by Country	311
Table 14 Other Application by Country.....	313
Table 15 Pharmaceutical by Country.....	316
Table 16 Venture by Country.....	318
Table 17 Clinical by Country.....	320
Table 18 Other Funding by Country	322
Table 19 2021 Clinical Laboratory Fee Schedule	325
Table 20 Pharmacogenomic Biomarkers	428

Table of Figures

Figure 1 FDA Approved Companion Diagnostics.....	30
Figure 2 Clinical Lab Spending 2014 to 2024	37
Figure 3 DNA Strands and Chromosomes	54
Figure 4 Karyogram of Human Chromosomes.....	55
Figure 5 Size of Various Genomes	58
Figure 6 Germline vs Somatic Mutations.....	62
Figure 7 Comparing Genomic Diagnostic and Traditional Testing	64
Figure 8 Percentage of World Population Over 65.....	71
Figure 9 Base Year Country Market Share Chart	295
Figure 10 CDx Market by Application - Base vs. Final Year.....	297
Figure 11 CDx Market by Application Base Year	298
Figure 12 CDx Market by Application Final Year.....	299
Figure 13 Application Type Share by Year.....	300
Figure 14 Funding Source – Base vs. Final Year	302
Figure 15 Funding Source Market Base Year	303
Figure 16 Funding Source Market Final Year	304
Figure 17 Funding Source Share by Year	305
Figure 18 Oncology Growth	308
Figure 19 Neurology Growth.....	310
Figure 20 Cardiology Growth	312
Figure 21 Other Application Growth.....	314

Figure 22 Pharmaceutical Growth 317

Figure 23 Venture Growth 319

Figure 24 Clinical Growth 321

Figure 25 Other Funding Growth 323